NGL FINECHEM
|
The Current P/E Ratio of NGL FINECHEM is 39.43.
Share Price | ₹1,326.0 | Jul 11,2025 |
Market Cap | ₹822.1 Cr | |
Earnings-TTM | ₹20.9 Cr | TTM-Consolidated Results |
Price/Earnings | 39.43x | Calculated as Market Cap/Earnings |
---|---|---|
Explore Stock Analytics |
Definition & Calculation of PE (Price/Earnings) ratio of NGL FINECHEM
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹822.1 Cr] as on Jul 11,2025
(/) Earnings [ ₹20.9 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ 39.43x ]
Thus, for NGL FINECHEM , the investors are currently willing to pay 39.43 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of NGL FINECHEM !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of NGL FINECHEM over the last five years.
Historical PE (Price/Earnings) ratio chart of NGL FINECHEM
PE Ratio Performance Analysis for NGL FINECHEM
- NGL FINECHEM 's p/e ratio for fiscal years ending Mar2024 to Mar2020 averaged 25.58x.
- NGL FINECHEM 's operated at median p/e ratio of 24.27x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, NGL FINECHEM 's p/e ratio peaked in Mar2023 at 36.22x.
- NGL FINECHEM 's p/e ratio hit its five-year low in Mar2021 of 16.74x.
How does NGL FINECHEM 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
---|---|---|---|
NGL FINECHEM | 20.85 | 39.43 | 822.1 |
SUN PHARMACEUTICAL INDUSTRIES LTD | 10,980.10 | 36.55 | 401,289.0 |
DIVIS LABORATORIES LTD | 2,191.00 | 82.79 | 181,397.0 |
CIPLA LTD | 5,291.05 | 22.67 | 119,955.0 |
TORRENT PHARMACEUTICALS LTD | 1,911.00 | 58.68 | 112,132.0 |
DR REDDYS LABORATORIES LTD | 5,703.50 | 18.35 | 104,657.0 |
MANKIND PHARMA LTD | 2,003.22 | 53.11 | 106,401.0 |
ZYDUS LIFESCIENCES LTD | 4,614.80 | 21.36 | 98,570.7 |
LUPIN LTD | 3,306.26 | 26.15 | 86,442.7 |
AUROBINDO PHARMA LTD | 3,515.26 | 18.58 | 65,308.2 |
ABBOTT INDIA LTD | 1,414.44 | 51.69 | 73,118.7 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs NGL FINECHEM 's P/E Ratio
Top 10 Industry Peers | PE Ratio |
---|---|
Min industry PE | 18.35x |
Max industry PE | 82.79x |
Median industry PE | 36.55x |
Average industry PE | 39.03x |
You may also like the below Video Courses